Vericel Corporation arrives at its May 7 Q1 earnings with a recovering share price, a meaningful short position that has been quietly unwinding, and analyst targets that still sit well above where the stock trades.
The stock added 5.9% on the week to close at $35.65 on Tuesday before slipping 3.4% on Wednesday. That follows a strong month — up 21.5% from late March lows — though the stock remains roughly flat year-to-date. The price recovery has come as short sellers have pulled back: SI has dropped 6% over the past week to just below 9.9% of the free float, down from a recent peak above 10.4% in early April. At around 8.7 days to cover, the position is not trivial, but the direction of travel is notable. Shorts have consistently reduced exposure since mid-April, trimming roughly 320,000 shares over the past two weeks.
The lending market tells the same story — the bear side is not adding pressure here. Cost to borrow has crept up 7.7% on the week to just 0.53%, barely above its 30-day average and among the cheapest borrow rates in the biotech space. Availability remains wide open relative to outstanding short interest. The ORTEX short score has also stepped down meaningfully, from 61.0 on April 15 to 58.4 today — still above the midpoint, but on a clear downward trend as positioning lightens. The options market adds a different texture: the put/call ratio is running at 1.93, very close to its 52-week high of 1.99, yet the z-score is a sharply negative 2.4 — meaning the PCR has dropped relative to its own recent range, suggesting put demand has eased from even more extreme levels. There is more protection in this name than usual, but slightly less than there was a week ago.
The Street remains constructive but has been systematically marking down targets. Truist Securities, the most active on this name, lowered its target from $48 to $42 on April 15 while keeping a Buy rating — the latest in a series of cuts that has moved Truist's target from $61 last April down to $42 today. HC Wainwright moved the other way in February, lifting to $64 after the last quarterly print, but that enthusiasm has not been shared broadly. The consensus mean target stands near $54.57, implying roughly 53% upside to current levels — a gap that in normal biotech conditions would read as bullish, but here reflects a stock that has persistently disappointed against elevated expectations. The EV/EBITDA multiple has compressed from around 19.5x thirty days ago to 18.4x today, a gentle de-rating even as the price recovered. The PE stands at 64.5x on consensus forward earnings of $0.43 per share.
The bull case rests on MACI volume growth and ASP improvements, with some forecasts pointing to 21% year-over-year MACI revenue growth in FY26 backed by strong biopsy-to-implant conversion rates. The bear case is more granular: a roughly 200 basis point downward revision to MACI revenue projections for FY26 and FY27, with concerns about physician adoption pace, the burn care segment, and execution risk around sales force expansion. Any single miss on the top line, the bears argue, could push the stock to historical valuation lows.
Institutional ownership adds some context. Soleus Capital — a specialist healthcare fund — reported a fresh 5% stake in Q1, marking an entirely new position of 2.55 million shares. That is the most pointed new institutional commitment in the holder table. BlackRock and Vanguard are the two largest holders at 15.1% and 7.0% respectively, both incrementally adding in Q1, though their moves are likely index-driven. Insider activity over the past 90 days has been net positive in share terms at roughly 72,900 shares, though that figure is driven by awards rather than open-market buying; actual cash sales from the CMO, COO, and CLO in February and March totalled over $1.7 million combined, a persistent but unremarkable pattern of executives monetising compensation awards near the $35–$38 range.
The earnings history warrants attention. The two most recent Q1 prints have both produced negative one-day reactions — down 6.2% and down 3.8% respectively — with five-day moves of -10.5% and -8.3%. With the stock already 21.5% off its recent lows heading into the May 7 event, the key question is whether the recovery in price has run ahead of the recovery in estimates — and whether Soleus's new conviction can hold if MACI volumes disappoint again.
See the live data behind this article on ORTEX.
Open VCEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
